Related stories
Nxera Pharma Licenses IBD Drug Candidate to AbbVie
Nxera will receive US$100 million upfront and is eligible for up to US$1.37 billion in development and other milestone payments under a global license agreement with AbbVie.
M impact | EQUITY | Nov 04, 2026, 08:46 AM UTC
和美药业 Delays Hong Kong Global Offering and Listing
和美药业 said it has decided to delay its global offering and listing in Hong Kong, citing current market conditions.
L impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Thangamayil Jewellery Reports September-Quarter Net Sales of 23.81 Billion Rupees
L impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Power Finance Q2 Consolidated Net Profit 60.34 Billion Rupees
M impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Redington shares rally 9.4% after record Q2 revenue and profit growth
Redington reported its highest-ever quarterly revenue in Q2 FY27, with growth across geographies and improved operating earnings. Shares reached an intraday high of ₹362 on the BSE
M impact | EQUITY | Nov 04, 2026, 08:41 AM UTC
Omani fintech Mamun raises $3 million in seed funding
Mamun will use the funding to expand Gulf-Asia trade finance. The company says it has facilitated nearly $20 million in financing since beginning operations in the fourth quarter o
M impact | EQUITY | Nov 04, 2026, 08:41 AM UTC